1 Using different methods for ranking predicted 1 coding cancer drivers based on mutations 2 0 20 40 Top 50 Top 100 Top 150 Top 200 Top N genes Number of validated driver genes CBNA_mutation_count CBNA_mutation_significance CBNA_mutation_function Fig A. CBNA with different methods for ranking predicted coding cancer drivers based on mutation burden The coding cancer drivers predicted by CBNA are ranked based on (1) mutation count, (2) mutation significance of mutation frequency and spectrum of patients, and (3) functional impact of mutations. The results of the methods are validated against the CGC. Each bar shows the number of validated cancer drivers of each method.
CBNA with different methods for ranking predicted coding cancer drivers based on mutation burden The coding cancer drivers predicted by CBNA are ranked based on (1) mutation count, (2) mutation significance of mutation frequency and spectrum of patients, and (3) functional impact of mutations. The results of the methods are validated against the CGC. Each bar shows the number of validated cancer drivers of each method.
The first approach to rank candidate coding cancer drivers is based on mutation 3 count. The second approach is based on (i) mutation frequency and spectrum of 4 patients, and (ii) mutation rates of genes incorporating expression level and replication 5 time, as the MutSigCV method does [1] . Another approach to rank cancer drivers 6 predicted by CBNA is based on the functional impact of mutations as OncodriveFM 7 does [2] . We compare these approaches and the result is illustrated in Fig. A . It can be 8 seen that the performance of CBNA using mutation count is better than the other 9 methods in all the cases.
2 Breakdown of known breast cancer driver genes 11 There are 80 known breast cancer genes in the well-curated set which are obtained 12 from [3] , [4] , [5] , and [6] . Of these 80 genes, 18 are filtered out by the PPI and miRNA 13 databases. For the remaining gene set, 19 genes are critical nodes, 8 are redundant 14 nodes, and 35 are ordinary nodes in the network created by CBNA. 15 3 Several genes enriched significantly in biological 16 processes and molecular functions 17 We conduct GO [7] enrichment analysis of coding non-mutation drivers for breast 18 cancer, which are predicted by our method. There are several predicted drivers which 19 are involved in various GO biological processes and GO molecular functions. We rank 20 enriched terms of GO biological process as well as GO molecular function based on the 21 number of the predicted drivers in an enriched term. The higher number of the 22 predicted drivers an enriched term has, the higher it is in the list. Then we select the 23 top 10 GO process terms and top 10 GO function terms. Among genes in the top GO 24 processes or top GO functions, we rank genes based on their occurrence in these 25 enriched terms. The higher number of occurrences a gene has, the higher it is in the list. 26
27
The heatmap of enrichment profiles for the top 20 predicted coding drivers of the The miRNA-TF-mRNA network of the normal state obtained by CBNA consists of 35 7,726 nodes and 31,053 directed edges. We apply the network control [8] to evaluate the 36 controllability of the network by identifying its MDNS. We find that the size of MDNS, 37 denoted as N D , is 2,680, accounting for 45.5% of nodes. We then classify nodes as 38 critical, ordinary, and redundant based on the change of N D upon their removal. In the 39 miRNA-TF-mRNA network of normal state, 11.2% of nodes are critical, 34% are 40 ordinary, and the remaining 54.8% are redundant (Fig. C(A) ). We find that critical 41 nodes have higher in-degrees/out-degrees compared with ordinary and redundant nodes, 42 which can be seen in the average in-degree/out-degree and accumulative 43 in-degree/out-degree distribution of nodes in Fig. C(B) and Fig. C(C) . 5 Epithelial-mesenchymal transition drivers 45 We apply CBNA to BRCA dataset to identify epithelial-mesenchymal transition (EMT) 46 drivers. These drivers are expected to drive the transition from epithelial state to 47 mesenchymal state in breast cancer patients.
49
To validate the result, we rank predicted EMT drivers based on their node degree 50 (i.e. the number of edges of a node) in the network of the mesenchymal condition, which 51 is built by our method. The higher degree a driver has, the higher it is in the ranked 52 driver list. We then validate the top 100 predicted coding EMT drivers with 53 mesenchymal genes in EMT signatures [9] and 17 predicted miRNA EMT drivers with 54 pro-mesenchymal miRNAs in EMT miRNAs [10] . There are 7 predicted coding EMT 55 drivers and 6 predicted miRNA EMT drivers in these known EMT gene lists. The 56 p-values are significant at 0.007 and 1.333e-07 respectively based on the hypergeometric 57 test. The p-value is calculated as the following. 
Fig D. Overlaps between candidate EMT drivers and known EMT genes
The chart shows the significant ovelaps of (A) coding candidate EMT drivers (top 100) and mesenchymal genes, (B) candidate miRNA EMT drivers and pro-mesenchymal miRNAs.
where N denotes the number of all genes of interest, K is the number of confirmed 59 drivers (i.e. genes in known EMT gene lists), M is the number of estimated drivers, and 60 n is the number of drivers validated.
62
The result is illustrated in Fig. D . 
